Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients
Launched by UNIVERSITY HOSPITAL HEIDELBERG · Jun 25, 2025
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to reduce the risk of falls in people with multiple myeloma, a type of cancer that affects the bones and blood. Falling is a common problem, especially for older adults, and it can lead to serious injuries, loss of independence, and a lower quality of life. People with cancer, including multiple myeloma, may have an even higher risk of falling, but there hasn’t been much research on this. This study aims to understand what factors increase the risk of falls in multiple myeloma patients and to test a special exercise program designed to improve strength and balance, helping to prevent falls and related injuries.
If you have multiple myeloma and are receiving treatment, you might be eligible to join if you are 18 or older, able to participate in exercise sessions at least three times a week, and can attend follow-up visits. You also need to be able to give informed consent and understand German well enough to complete questionnaires. The study will include an initial assessment to check your risk of falling, followed by a personalized training program focused on exercises to improve your strength and balance. This program is meant to help you stay safer and more independent in your daily life. Participation requires a commitment to regular exercise and follow-up visits, and those with physical or mental conditions that would make participation difficult may not be eligible.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with multiple myeloma requiring therapy (at least 6 months of systemic therapy)
- • ECOG status ≤ 3
- • Age ≥18 years
- • Patients who state that they want to carry out the training program at least 3 times/week and participate in the planned follow-up visits
- • Ability to give informed consent
- • Written consent to participate in the study
- • Sufficient written and spoken German to complete the questionnaire
- Exclusion Criteria:
- • Any physical or mental limitations that would prevent participation in the training program or the planned follow-up checks.
About University Hospital Heidelberg
University Hospital Heidelberg is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a key player in translational medicine, the hospital integrates cutting-edge scientific discoveries with patient care, facilitating a robust environment for clinical trials. With a diverse range of specialties and a multidisciplinary approach, University Hospital Heidelberg aims to improve therapeutic outcomes and enhance the quality of life for patients through evidence-based practices. The institution is dedicated to fostering collaborations with academic partners, industry stakeholders, and regulatory bodies to drive forward-looking research initiatives and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, , Germany
Patients applied
Trial Officials
Dapunt
Study Chair
University Hospital Heidelberg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported